DYN (STOCKS)
Dyne Therapeutics, Inc. Common Stock
$19.200000
+0.520000 (+2.78%)
Prev close: $18.680000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- John G. Cox
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,132.21M
- Employees
- 206
- P/E (TTM)
- -5.36
- P/B (TTM)
- 3.17
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.76 | $-0.78 | +0.0177 | +2.28% |
|
Sep 2025 (Q3)
|
$-0.76 | $-0.85 | +0.0857 | +10.13% |
|
Jun 2025 (Q2)
|
$-0.97 | $-0.96 | -0.0058 | -0.60% |
|
Mar 2025 (Q1)
|
$-1.05 | $-0.89 | -0.1620 | -18.24% |
Financial Statements
| Revenues | $1.17B |
| Benefits Costs and Expenses | $3.26B |
| Cost Of Revenue | $793.00M |
| Cost Of Revenue, Goods | $793.00M |
| Costs And Expenses | $3.26B |
| Gross Profit | $378.00M |
| Operating Expenses | $492.00M |
| Operating Income/Loss | -$114.00M |
| Income/Loss Before Equity Method Investments | -$2.09B |
| Income/Loss From Continuing Operations After Tax | -$1.90B |
| Income/Loss From Continuing Operations Before Tax | -$2.09B |
| Income Tax Expense/Benefit | -$189.00M |
| Income Tax Expense/Benefit, Deferred | -$190.00M |
| Interest Expense, Operating | $244.00M |
| Net Income/Loss | -$1.90B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$1.90B |
| Net Income/Loss Available To Common Stockholders, Basic | -$1.90B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Assets | $6.80B |
| Current Assets | $2.90B |
| Inventory | $132.00M |
| Other Current Assets | $2.77B |
| Noncurrent Assets | $3.90B |
| Fixed Assets | $3.29B |
| Intangible Assets | $149.00M |
| Other Non-current Assets | $458.00M |
| Liabilities | $7.96B |
| Current Liabilities | $1.67B |
| Accounts Payable | $92.00M |
| Other Current Liabilities | $1.58B |
| Noncurrent Liabilities | $6.29B |
| Long-term Debt | $1.68B |
| Other Non-current Liabilities | $4.61B |
| Equity | -$1.16B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$1.16B |
| Liabilities And Equity | $6.80B |
| Net Cash Flow From Operating Activities | -$22.00M |
| Net Cash Flow From Operating Activities, Continuing | -$22.00M |
| Net Cash Flow From Investing Activities | $242.00M |
| Net Cash Flow From Investing Activities, Continuing | $242.00M |
| Net Cash Flow From Financing Activities | $82.00M |
| Net Cash Flow From Financing Activities, Continuing | $82.00M |
| Net Cash Flow | $302.00M |
| Net Cash Flow, Continuing | $302.00M |
| Comprehensive Income/Loss | -$1.90B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$1.90B |
| Other Comprehensive Income/Loss | $0.00 |